@techcrunch.com 2 years ago
Flagship Pioneering’s new venture is betting on tRNA to treat “thousands of diseases”
@xconomy.com 3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com 3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com 3 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com 4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com 4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com 4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com 4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic
@xconomy.com 5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care